Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$9.35 USD

9.35
4,422,333

-0.26 (-2.71%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $9.42 +0.07 (0.75%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Novavax (NVAX) Q4 Earnings & Revenues Miss Estimates, Stock Down

Novavax (NVAX) reports worse-than-expected financial performance in the fourth quarter of 2022, with earnings and revenues both missing the Zacks Consensus Estimate. Stock plunges 26.1% in response to the news.

Novavax (NVAX) Reports Q4 Loss, Misses Revenue Estimates

Novavax (NVAX) delivered earnings and revenue surprises of -147.83% and 5.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More

Let us look at four drug and biotech companies, NVAX, IOVA, ALLO, SRPT and FATE, which are gearing up for their earnings release.

Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

Novavax (NVAX) closed at $9.07 in the latest trading session, marking a -0.33% move from the prior day.

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

Novavax (NVAX) closed the most recent trading day at $9.99, moving -1.96% from the previous trading session.

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $9.88, marking a +1.02% move from the previous day.

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

On Novavax's (NVAX) fourth-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.

Omega Therapeutics, Inc. (OMGA) Surges 37.2%: Is This an Indication of Further Gains?

Omega Therapeutics, Inc. (OMGA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

Novavax (NVAX) closed the most recent trading day at $11.09, moving -1.25% from the previous trading session.

The Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and Novavax

Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.

Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised)

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy

An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

Novavax (NVAX) closed at $10.98 in the latest trading session, marking a -1.17% move from the prior day.

Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $11.55, marking a -0.6% move from the previous day.

Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea

Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

Novavax (NVAX) closed at $12.41 in the latest trading session, marking a +1.22% move from the prior day.

Novavax (NVAX) Names John Jacobs as New CEO, Shares Rise

Novavax (NVAX) appoints John C. Jacobs as its new president and chief executive officer, effective Jan 23, 2023.

The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax

Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax are included in this Analyst Blog.

Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More

Updates from Geron (GERN) and VERA are the key highlights from the biotech sector during the past week.

Novavax (NVAX) Starts A New Study on COVID-Flu Combo Jab

Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80 years.

Company News for Dec 16, 2022

Companies in The News Are: NFLX,WBD,NVAX,META

Pfizer (PFE), BNTX's COVID-Flu Combo Jab Gets FDA Fast Track Tag

The FDA grants fast-track designation to Pfizer (PFE)/BioNTech's (BNTX) early-stage combination vaccine candidate, which targets two respiratory diseases - influenza and COVID-19.

Novavax (NVAX) Down 7.6% Since Last Earnings Report: Can It Rebound?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.